Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01947348 |
Recruitment Status : Unknown
Verified September 2014 by barbara krutchkoff, Institute of Regenerative and Cellular Medicine.
Recruitment status was: Recruiting
First Posted : September 20, 2013
Last Update Posted : September 4, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis | Procedure: treatment with A3 SVF | Not Applicable |
This is a prospective non-randomized, clinical study of 30 patients to determine safety and treatment potential of A3(Adult Autologous Adipose) SVF for the pain and inflammation associated with Osteoarthritis.
Patients will be treated for Osteoarthritis due to degeneration or chronic injury. They will be given autologous SVF extract derived by the A3 method mixed with activated platelets from a PRP(platelet rich plasma) preparation as direct injections to the effected joints. Outcomes will be tracked with WOMAC (Western Ontario and McMaster Universities Arthritis Index), AUSCAN(Australian Hand Osteoarthritis Index) scores, and a general blood panel in order to evaluate systemic effects.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis |
Study Start Date : | September 2012 |
Estimated Primary Completion Date : | September 2015 |
Estimated Study Completion Date : | September 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: treatment with A3 SVF
These patients that have been treated. The control patients that have not been treated.
|
Procedure: treatment with A3 SVF
Treatment interarticular and IV with A3 SVF
Other Name: A3 SVF, Cell Extracts, Adipose Derived Stem Cells |
- Pain and Inflammation - WOMAC scores, comprehensive inflammation blood panel [ Time Frame: one year ]
- Pain and Mobility Assessment [ Time Frame: one year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
- Patients range from 15-90 years of age.
- Female patients not pregnant or lactating.
- Patients with a history of or current corticosteroid therapy will only be eligible if use is suspended from 1 month prior to cell therapy.
- Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
- Patients with adequate renal function, creatinine ≤ 1.5 mg/dl.
- Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT <1.5×control.
Exclusion Criteria:
- Diagnosis of cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision.
- Signs and symptoms of clinically significant cardiac disease.
- Diagnosis of a transient ischemic attack in the 6 months prior to screening,
- Known allergy to anesthetic or any other components of study.
- Patients infected with hepatitis B, C or HIV.
- Patients with Body Mass Index (BMI) > 39kg/m2 .
- Any other cardiovascular illness that in the opinion of the investigator would render a patient unsuitable to participate in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01947348
Contact: John Huh, MD | 213 384 1717 |
United States, California | |
Dr John Huh | Recruiting |
Los Angeles, California, United States, 90020 | |
Contact: John Huh, MD 213-384-1717 drjhuh@gmail.com | |
Principal Investigator: John Huh, MD |
Study Chair: | Barbara Krutchkoff | Institute of Regenerative and Cellular Medicine | |
Principal Investigator: | John Huh, MD | ICMS |
Responsible Party: | barbara krutchkoff, Dr John Huh, Los Angeles, Institute of Regenerative and Cellular Medicine |
ClinicalTrials.gov Identifier: | NCT01947348 |
Other Study ID Numbers: |
A3-912-OA-801 |
First Posted: | September 20, 2013 Key Record Dates |
Last Update Posted: | September 4, 2014 |
Last Verified: | September 2014 |
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |